Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 23;220(4):e20220686. doi: 10.1084/jem.20220686

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Sun et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure S1. — STAT3 is intrinsically critical for the effector function of CD8⁺ T cells. (A) mRNA level of STAT3 in CD8⁺ T cells from peripheral blood or tumors in human cancer patients (GEO accession nos. GSE99254, GSE108989, and GSE98638). scRNA-seq data of CD8⁺ T cells in tumors and peripheral blood from lung, CRC, and HCC patients were previously processed and uploaded by others (http://crc.cancer-pku.cn/, http://hcc.cancer-pku.cn/, http://lung.cancer-pku.cn/; Guo et al., 2018; Zhang et al., 2018; Zheng et al., 2017), and we obtained the STAT3 expression values from the above websites. The expression unit was normalized expression/log₂^(TPM+1). We compared the STAT3 expression values in CD8⁺ T cells from peripheral blood, and in PD-1–negative (PDCD1 expression value = 0) and –positive (PDCD1 expression value >0) CD8⁺ T cells from tumors. (B) STAT3 protein expression in CD8⁺ T cells from spleens, TDLNs, and tumors in B16-OVA (upper plot) and E.G7 (bottom plot) models. (C) mRNA levels of Stat3 in CD8⁺ T cells from TDLNs and tumors in B16-OVA (left panel) and E.G7 (right panel) models. (D) Frequencies of CD8⁺ T cells in thymuses, spleens, and lymph nodes in 6- to 8-wk-old Stat3^fl/fl (n = 5) and Stat3^fl/flCd8a^Cre (n = 5) mice. (E) Ratios of CD8⁺ T cells to CD4⁺ T cells in the thymuses, spleens, and lymph nodes from 6- to 8-wk-old Stat3^fl/fl (n = 5) and Stat3^fl/flCd8a^Cre (n = 5) mice. (F) Representative plots (left panel) and quantifications (right panel) of CD44 and CD62L expression on CD8⁺ T cells in the spleens and lymph nodes from 6- to 8-wk-old Stat3^fl/fl (n = 5) and Stat3^fl/flCd8a^Cre (n = 5) mice. (G) Ratios of CD8⁺ T cells to CD4⁺ T cells in TDLNs and tumors. (H) Representative plots (left panel) and quantifications (right panel) of H-2K(b) tetramer⁺ CD8⁺ T cells among total CD8⁺ T cells from TDLNs and E.G7 tumors. (I) Representative plots (left panel) and quantifications (right panel) of CD44⁺ PD-1⁺ CD8⁺ T cells among total CD8⁺ T cells from TDLNs and E.G7 tumors. (J) OT-I TIL frequencies among total CD8+T cells from TDLNs in B16-OVA model on day 20 after tumor inoculation. (K) Representative plots (left panel) and quantifications (right panel) of Ki-67 expression in OT-I TILs from B16-OVA tumors on day 20 after tumor inoculation. (L) Representative plots (left panel) and quantifications (right panel) of Ki-67 expression in splenic CD44⁺ CD8⁺ T cells on day 8 after LM-OVA infection. Data are pooled from three independent experiments (H), or are representative of two (B–F, G [left], J, and L) or three (G [right], I, and K) independent experiments. Data are shown as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 by one-way ANOVA (A and C), unpaired two-tailed Student’s t test (D–I and L) or paired two-tailed Student’s t test (J and K). Source data are available for this figure: SourceData FS1.